COMMUNITY pharmacies are being invited to open accounts with Medlab Clinical in order to access the company's new NanaBis oromucosal pain spray, which is available via the Medicinal Cannabis Medicines Portal (MCMP) effective from today.
NanaBis is a non-ARTG schedule 8 medication which is indicated for the improvement of systems related to intractable pain in cancer patients.
The product is currently in clinical trial (PD 24 Apr) and is available under the Approved Prescriber Scheme and Special Access Scheme Category B through the MCMP.
The MCMP is an initiative of PharmaPrograms, developed by Sinapse Pty Ltd as an IT-enabled health system that helps patients by improving access to pharmaceutical treatments and programs with the support of their doctor and pharmacist.
Prior to ordering NanaBis for patients, pharmacies will need an account with Medlab, with Sinapse urging that this be set up as soon as possible to ensure the pharmacy is ready for the first request.
Account opening procedures require the pharmacy to demonstrate its qualification for storing and handling Schedule 8 controlled drugs, in the form of a Pharmacy Registration Certificate or an Agreement with Medicare and the matching owner pharmacist's AHPRA registration certificate.
In addition to facilitating supply of NanaBis, a structured pharmacy support program is an integral part of the MCMP, which provides a streamlined process for medicinal cannabis prescribing and dispensing.
Sinapse noted there were also additional pharmacy and prescriber resources available via the MCMP website, including a CMI document and a NanaBis pricing table.
More information is available on 1300 364 231 or via email on mcmp@pharmaprograms.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Apr 18
